Atossa Therapeutics Files 8-K
Ticker: ATOS · Form: 8-K · Filed: Dec 4, 2025 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.18 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: ATOS
TL;DR
ATOS filed an 8-K, likely routine updates. Monitor for details.
AI Summary
On December 4, 2025, Atossa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Atossa Therapeutics is providing updates or submitting required documentation to the SEC, which could relate to ongoing business activities or financial reporting.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification without specific material events or financial disclosures that would immediately impact risk.
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- 20251204 (date) — Date of Report
FAQ
What specific "Other Events" are being reported by Atossa Therapeutics, Inc. in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported; it only lists the item category.
What "Financial Statements and Exhibits" are included with this 8-K filing?
The excerpt states that "Financial Statements and Exhibits" are part of the filing, but does not list their specific contents.
What is the Central Index Key (CIK) for Atossa Therapeutics, Inc.?
The CIK for Atossa Therapeutics, Inc. is 0001488039.
What is the SEC File Number for Atossa Therapeutics, Inc.?
The SEC File Number for Atossa Therapeutics, Inc. is 001-35610.
When was Atossa Therapeutics, Inc. formerly known as Atossa Genetics Inc.?
Atossa Therapeutics, Inc. was formerly known as Atossa Genetics Inc. prior to a name change on March 25, 2010.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-12-04 08:15:24
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
Filing Documents
- atos-20251204.htm (8-K) — 55KB
- atos-ex99_1.htm (EX-99.1) — 21KB
- img248274862_0.jpg (GRAPHIC) — 5KB
- 0001193125-25-307516.txt ( ) — 218KB
- atos-20251204.xsd (EX-101.SCH) — 45KB
- atos-20251204_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events On December 4, 2025, Atossa Therapeutics, Inc. (the "Company") issued a press release announcing the completion of a Type C meeting with the U.S. Food and Drug Administration ("FDA") on November 17, 2025 to review regulatory strategy for advancing (Z)-endoxifen. The meeting provided the Company with FDA feedback on regulatory pathways and development options across metastatic disease, neoadjuvant treatment, and breast cancer risk-reduction settings. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description of Exhibit 99.1 Press release, dated December 4, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: December 4, 2025 By: /s/ Mark J. Daniel Mark J. Daniel Chief Financial Officer (Principal Financial and Accounting Officer)